Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]
Gupta M, Shukla J.
europepmc +1 more source
Correction: Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes. [PDF]
Saito R, Harada N.
europepmc +1 more source
Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. [PDF]
Kubota-Okamoto S +17 more
europepmc +1 more source
Antiobesity Medications for Older Adults-the New, the Good, the Bad, and the Unknown. [PDF]
Pendrey A, Sevilla-Martir J.
europepmc +1 more source
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders. [PDF]
Farrugia MA +5 more
europepmc +1 more source
Pediatric reference values for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon in children and adolescents. [PDF]
Lawaetz TWH +9 more
europepmc +1 more source
Betagenin: New intestine-derived hormone which ameliorates diabetes. [PDF]
Kim YK, Won K.
europepmc +1 more source
From Fermented Sugar to Incretin Therapeutics: Reuniting Metabolism and Addiction. [PDF]
Gold MS, Blumenthal DM.
europepmc +1 more source
Incretin-Related Pathology and Serum Exosome Detection in Experimental Alcohol-Related Brain Damage. [PDF]
de la Monte SM, Tong M, Yang Y.
europepmc +1 more source

